Introduction: the ethanol molecule
==================================

Ethanol became part of our ecology over 200 million years ago when yeast started fermenting carbohydrates in fruits and grains, generating ethanol (Ratcliff et al., [@B53]). Animals were subsequently exposed to ethanol in these naturally fermented products. It has been proposed (Duddley, [@B15]; Dominy et al., [@B14]) that animals that perceived ethanol as a pleasant substance had an evolutionary advantage since they also increased the intake of calories from these sources.

The pleasant effects of alcohol explain why humans engaged in manufacturing it. The book of Anni, in 1700 BC Egypt describes an overt intoxication and the rules of proper behavior to be followed in a beer shop. Subsequently, its distillation is described in 900 AD and its production and massive consumption were brought by the Industrial Revolution (Hogarth, [@B24]). While in moderate doses alcohol generates motivational and reinforcing effects, in high doses it can generate aversion, inducing cognitive deficits, motor incoordination and emesis.

There is general agreement that in high concentrations ethanol modifies some neurotransmitter receptors by allosteric binding to their hydrophobic pockets, for example on the gamma-amino butyric acid receptor (GABA-A) (Harris and Allan, [@B22]; Suzdak et al., [@B70]; Huidobro-Toro et al., [@B25]). These hydrophobic pockets are also modifiable, with similar effects, by barbiturates and anesthetics, such as enfluorane, isofluorane and other long chain aliphatic alcohols (Levitan et al., [@B34]; Pritchett et al., [@B46]; Mihic et al., [@B39], [@B40]; Krasowski et al., [@B32]).

Another receptor upon which ethanol generates hypnotic/anesthetic effects is the N-Methyl-D-Aspartate (NMDA) glutamate receptor (Lovinger et al., [@B36]; Weight et al., [@B79]). Ethanol binds allosterically to the NMDA receptor (Wright et al., [@B81]; Wirkner et al., [@B80]), an effect that leads to the interruption of cognitive processes, consolidation of memory and anesthesia (Robbins and Murphy, [@B57]). The hydrophobic pockets in the NMDA receptor can also be modified by anesthetics of diverse structures such as halothane, cyclopropane and xenon (Ogata et al., [@B43]). However, several studies indicate that the hypnotic and anesthetic effects of ethanol do not correlate with its rewarding properties (Riley et al., [@B55]; Daoust et al., [@B12]; Elmer et al., [@B16]).

Acetaldehyde as a mediator of the effects of ethanol
====================================================

Crabbe et al. ([@B11]) reviewed the literature on the putative role of 93 genes likely involved in the effects of ethanol. Those involved with greater frequency were alcohol dehydrogenase and aldehyde dehydrogenase. The present review deals primarily with studies that show the effects generated by increasing or reducing acetaldehyde levels and/or the ability of the liver and brain to generate it. The studies were conducted in Wistar-derived rats selectively bred for over 80 generations, which led to two lines of rats: the UChA (abstainer) and the UChB (bibulous). The studies to be presented dovetail with many other studies described in this issue and potentiate the concept that acetaldehyde is a major contributor of the effects of ethanol, both aversive and rewarding.

Ethanol (CH3-CH2OH) is a small and relatively non-reactive molecule, thus requiring high concentrations to generate its effects. In high concentrations ethanol mainly interacts with hydrophobic pockets in proteins. On the other hand, acetaldehyde (CH3-CHO) is able to bind to amines (e.g., lysine residues) in proteins, generating Schiff bases (CH~3~-C=N-CH~2~-R), also binding to dopamine generating salsolinol, which has also been studied as a mediator of ethanol effects. Recently, Juricic et al. ([@B27]) confirmed early studies by King et al. ([@B31]) showing that acetaldehyde can, in addition to generating salsolinol, condense non-enzymatically with a carbon vicinal to a hydroxyl group in dopamine, yielding isosalsolinol (Figure [1](#F1){ref-type="fig"}). It was shown that commercial salsolinol (Sigma-Aldrich, sold prior to 2012) used in this field\[,\] is a mixture of four dopamine-acetaldehyde condensation products: *(R)- and (S)- salsolinol* (85%) and *(R)- and (S)- isosalsolinol* (10--15%).

![**Acetaldehyde condensation with dopamine.** Products formed in the non-enzymatic condensation are (R)- and (S)-salsolinol and (R)- and (S)- isosalsolinol (from Juricic et al., [@B27]).](fnbeh-07-00080-g0001){#F1}

Aversive effects of liver-generated acetaldehyde
================================================

Among the first studies that described powerful effects of acetaldehyde were those seen in East Asians when consuming ethanol. Studies in the 80\'s demonstrated that 20--40% of individuals of East Asian origin (e.g., Japan, China, Korea) develop dysphoric effects when consuming alcohol; the effects often include peripheral vasodilatation and overt facial flushing, tachycardia, headache, nausea and emesis (Mizoi et al., [@B41]). Such individuals carry a point mutation in the gene that codes for the high affinity (low *K~m~*) mitochondrial aldehyde dehydrogenase-2 (*ALDH*2^\*^2), a mutation that greatly reduces its affinity for NAD^+^, thus generating a virtually inactive dehydrogenase. Subjects carrying the *ALDH*2^\*^2 polymorphism develop large increases in blood acetaldehyde (reaching 80--100 μM; over 5-fold that of subjects who carry the wild-type enzyme: *ALDH*2^\*^1). It is important to note that these increases are due not only to the inability of liver to oxidize acetaldehyde into acetate, but also the inability of peripheral tissues and vascular tissues to oxidize acetaldehyde; tissues which also express the gene for high affinity mitochondrial aldehyde dehydrogenase. In venous blood of individuals carrying the normal ALDH2^\*^1 enzyme, the levels of acetaldehyde are virtually nil; while levels of the order of 15--20 μM are found when arterial blood is sampled (see Quintanilla et al., [@B50]). The marked ability of endothelial tissues to metabolize acetaldehyde is of major importance in understanding why a lipophilic metabolite such as acetaldehyde does not cross the tight-junction cells that constitute the blood brain barrier (*vide infra*), and why the effects of acetaldehyde are so different in the periphery vs. the central nervous system.

A number of studies have shown that individuals carrying the *ALDH*2^\*^2 allele are protected between 66% (heterozygous *ALDH*2^\*^1/*ALDH*2^\*^2) and 99% (homozygous *ALDH*2^\*^2/*ALDH*2^\*^2) against alcoholism (Harada et al., [@B21]; Thomasson et al., [@B75]; Higuchi, [@B23]; Tu and Israel, [@B76]; Chen et al., [@B8]; Luczak et al., [@B37]; Zintzaras et al., [@B84]). Hence, disulfiram (Antabuse®), a drug that non-specifically inhibits ALDH2, is the most efficient drug in the treatment of alcoholism provided its *daily intake* is secured by another person Chick et al. ([@B9]), see meta-analysis by Jørgensen et al. ([@B26]). Recent studies in animals (Escrig et al., [@B18]) show that disulfiram, while not showing behavioral effects on its own, reverses the anxiolytic effects of ethanol or shows anxiogenic effects. The administration of a large dose of acetaldehyde (100 mg/Kg) being anxiogenic *per se*.

Animal studies also support the concept that alcohol is a prodrug *vis-a vis* their aversive effects. Rats of the UChA line (virtually Abstainer) display a mutation in the *aldh2* gene (Sapag et al., [@B62]; see Quintanilla et al., [@B48]), which codes for an enzyme with a higher *K~m~* for NAD^+^ and a lower Vmax that the ALDH2 of heavy drinker animals (UChB; Bibulous). Further, the levels of arterial acetaldehyde display a large "acetaldehyde burst," reaching 40--50 μM (vs. 10--20 μM for controls), which deters their alcohol intake (Quintanilla et al., [@B52]). The mutation in the ALDH2 gene accounts for 50--60% of the low ethanol intake of UChA rats (Quintanilla et al., [@B51]).

Additional evidence that systemic acetaldehyde is aversive was seen in gene modification studies that inhibited ALDH2 activity and elevated blood acetaldehyde levels. In studies by Ocaranza et al. ([@B42]), UChB (drinker) rats were allowed access to 10% ethanol and water for 60 days (intakes of 7--8 g ethanol/kg/day), and were deprived of ethanol for 3 days. At the time of deprivation animals were injected an adenoviral vector (preferential liver tropism, but no crossing of blood-brain barrier) coding for an antisense RNA against ALDH2 mRNA, which lowered liver ALDH2 activity by 80--90% (*p* \< 0.001). When ethanol access was re-allowed, control (empty virus) animals ingested 1.2 g ethanol/kg/60 min (10-fold higher than a naïve UChB) while animals treated with the anti ALDH2 antisense ingested 0.5--0.6 g ethanol/kg/60 min (*p* \< 0.005). This inhibitory effect *remained constant* for the 34 days of the study. Acetaldehyde levels of animals that received the antisense against ALDH2 were of the order of 60 vs. 15--20 μM in controls.

In another study (Rivera-Meza et al., [@B56]), alcohol intake by UChB rats was reduced by 50% by the transfer into the liver (via an adenoviral vector) a rat homolog of the fast human alcohol dehydrogenase ADH1B^\*^2 (ADH-47His) which elevated 6-fold liver ADH activity. In these studies, arterial acetaldehyde levels in the ADH1B^\*^2 transduced animals increased from 20 to 80 μM after the i.p administration of 1.0 g ethanol/kg. These studies, in addition to confirming that increases in acetaldehyde at *physiological levels* generate alcohol aversion in the animals, explain a large number of studies showing that humans carrying the *ADH*1*B*^\*^2 (*ADH-47His*) gene are protected against alcoholism (see meta-analysis by Zintzaras et al., [@B84]). The lack of understanding of why this enzyme protected against alcoholism stems from the fact that acetaldehyde in humans carrying the *ADH*1*B*^\*^2 was determined in venous blood; being close to zero. As indicated earlier, venous blood, after having perfused the rich ALDH2^\*^1 peripheral tissues are devoid of acetaldehyde.

From the above, genetic and pharmacokinetic evidence indicates that blood acetaldehyde in concentrations of 40--80 μM is aversive to animals and to humans. The mechanism by which ethanol generates vasodilatation, hypotension and nausea could be the release of histamine from mast cells (Shimoda et al., [@B63]). However, antihistaminic drugs do not increase the intake of ethanol in low drinker UChA rats (Quintanilla and Tampier, unpublished). We would like to point out that it is not clear if the aversive effects of acetaldehyde are generated in the periphery beyond the liver or actually start in nerves terminals that travel from the liver to the CNS, a matter that requires study.

Brain acetaldehyde as a mediator of the rewarding effects of ethanol
====================================================================

Alcohol is absorbed from the stomach and intestine and is distributed throughout the body, reaching identical concentrations in the water of all tissues, including the brain. Ethanol is metabolized mainly in the liver by alcohol dehydrogenase (*K~m~* = 2 mM) generating acetaldehyde, which is further oxidized to acetate by a ubiquitous high affinity aldehyde dehydrogenase (*K~m~* \< 0.2 μM). Other enzymes that oxidize ethanol into acetaldehyde are catalase and cytochrome p4502E1 (Figure [2](#F2){ref-type="fig"}). These latter enzymes play a minor role in metabolizing ethanol in the liver (Mezey, [@B38]; Khanna and Israel, [@B30]).

![**Metabolism of ethanol into acetaldehyde by three enzymatic systems.** In the liver alcohol dehydrogenase (ADH) plays a major role, while catalase and cytochrome P450 (CYP2E1) play minor roles. In the brain, ADH (ADH1) is not expressed, but catalase mainly, and CYP2E1 to a minor extent, metabolize ethanol into acetaldehyde. Aldehyde dehydrogenase-2 (ALDH2) is present in virtually all cells (Drawn from Zimatkin et al., [@B83]).](fnbeh-07-00080-g0002){#F2}

An important question in this field is whether liver-generated systemic acetaldehyde (normally not exceeding 20 μM in arterial blood after ethanol intake) can cross the blood brain barrier. Studies indicate that since the capillaries of the blood brain barrier have tight junctions (rather than open pores) acetaldehyde must first enter the ALDH2-rich endothelial cells of the barrier, which clear the acetaldehyde. Thus, under normal conditions of ethanol metabolism, systemic acetaldehyde does not cross the blood brain barrier (Eriksson, [@B17]; Lindros and Hillbom, [@B35]; Peterson and Tabakoff, [@B45]; Stowell et al., [@B69]). Only when systemic concentrations exceed 100 μM, following the administration of systemic acetaldehyde, acetaldehyde enters the CNS (Tabakoff et al., [@B71]). High concentrations of brain acetaldehyde can also be attained by the systemic (i.p. or s.c.) administration high doses of acetaldehyde.

Alcohol dehydrogenase is not expressed in the brain (see Zimatkin et al., [@B83]; Deitrich, [@B13]), however, acetaldehyde can be generated from ethanol by the catalase reaction, and to a minor extent by CYP2E1, both enzymes present in brain (Tampier and Mardones, [@B72]; Aragon et al., [@B5]; Gill et al., [@B19]; Zimatkin et al., [@B83]). *In vitro* studies indicate that catalase generates 60--70% of brain acetaldehyde while CYP2E1 some 20% (Zimatkin et al., [@B83]). *In vivo* studies by Zimatkin and Buben ([@B82]) showed that ethanol infusion into the cerebral ventricles can generate acetaldehyde (achieving 60 μM), as detected in the cerebrospinal fluid. However, the concentrations of ethanol infused (85--90 mM) were in the anesthetic range (legal limits in most countries are 6--17 mM). In these studies, the catalase inhibitor aminotriazole reduced acetaldehyde levels in the cisterna magna. While such studies were promising in pointing out a major effect of catalase in acetaldehyde generation, the low specificity of aminotriazole required caution.

The question remains as to whether enough acetaldehyde is generated following a moderate ethanol intake to induce pharmacological effects. Studies in which aminotriazole was administered showed a reduction in voluntary ethanol intake by rats (Aragon and Amit, [@B4]; Tampier et al., [@B74]). However, aminotriazole also inhibited the consumption of food and of saccharine solutions (Rotzinger et al., [@B61]; Tampier et al., [@B74]), indicating non-specific actions. With a more direct approach, Ledesma and Aragon ([@B33]) showed that reducing brain hydrogen peroxide levels (required by catalase to oxidize ethanol to acetaldehyde) reduced alcohol-induced conditioned place preference. Most early studies in the field have been conducted by either administering large doses of acetaldehyde or by the use of inhibitors or inducers of catalase. The reader is referred to recent reviews in this field (Quertemont et al., [@B47]; Deitrich, [@B13]; Correa et al., [@B10]). Overall, the field generally agrees with the view that acetaldehyde mediates the reinforcing effects of ethanol; however, the methodologies used to achieve such consensus are varied, in some cases employing non-physiological concentrations and routes of administration of ethanol or acetaldehyde or non-specific inhibitors.

Early studies showed that rats self-administer acetaldehyde intracerebrally (Amit et al., [@B2]; Brown et al., [@B7]; Amit and Smith, [@B3]), indicating a reinforcing effect of this metabolite at the central nervous system level. Rodd et al. ([@B59]) demonstrated that rats selectively bred as alcohol drinkers (strain P of Indianapolis) self-administer both ethanol and acetaldehyde into the brain ventral tegmental area (VTA). Acetaldehyde (6 × 10^−6^ M) showed reinforcing effects at concentrations that were 1000 smaller than those required for ethanol (17 × 10^−3^ M) self-administration. The question remained as to whether enough acetaldehyde is generated in the brain to develop rewarding and reinforcing effects *when ethanol is consumed orally*.

Recently, a specific gene blocking technique allowed inhibiting brain catalase synthesis. Karahanian et al. ([@B29]) developed lentiviral vectors coding a shRNA designed to inhibit the synthesis of catalase. Lentiviral vectors permanently integrate into the cell genome the genes they carry. A single stereotaxic administration of an anti-catalase lentiviral vector (anticatalase-lenti) into the VTA, which reduced catalase levels by 70--80% (Quintanilla et al., [@B49]), virtually abolished the voluntary ethanol consumption (up to 95%) by drinker UChB rats for 40--50 days (Karahanian et al., Figure [3](#F3){ref-type="fig"}). The lentiviral anticatalase shRNA administration also abolished the increased release of dopamine in nucleus accumbens induced by ethanol administration (Figure [4](#F4){ref-type="fig"}). It is noteworthy that rats were not unduly affected (water intake, body weight, behavior) by the administration of the anticatalase lentiviral vector (Karahanian et al., [@B29]), as in the brain enzymes other than catalase are mainly responsible for the elimination of hydrogen peroxide (Halliwell, [@B20]), namely glutathione peroxidases and most active peroxiredoxins (Turrens, [@B77]; Rhee et al., [@B54]). Overall, the rewarding effects of ethanol appear to be mediated by acetaldehyde generated in the brain by the action of catalase. One can hypothesize that an increased ability of VTA to generate acetaldehyde, induced by genetic modification, should also demonstrate an increased rewarding effect of ethanol. This was tested by the administration into the VTA of a lentiviral vector coding for liver alcohol dehydrogenase. In these studies, to avoid a ceiling of the rewarding effect of acetaldehyde generated by catalase (when 10% ethanol is available to the animals, ethanol intake approaches the rate of whole body degradation), animals were allowed access to 5% ethanol and water. As can be seen in Figure [5](#F5){ref-type="fig"}, animals transduced with the liver alcohol dehydrogenase (ADH) into the VTA significantly increased their ethanol intake compared to that of animals administered the control vector. The animals administered the vector coding liver ADH or the control vector did not show differences in body weight or behavior.

![**Virtual long-lasting abolition of ethanol intake following the single administration of an anticatalase viral vector into the brain ventral tegmental area (VTA). (A)** Ethanol drinker rats (UChB line) were microinjected into the VTA 1.0 microliter (8 × 10^4^ particles) of a lentiviral vector coding for an shRNA against catalase mRNA. Controls received the empty lentiviral vector. Four days after the vector injection animals had 24-h access to 10% ethanol and water. **(B)** Animal weight was not affected by the anticatalase vector. Water intake (not shown) was not modified either (from Karahanian et al., [@B29]). Replicate studies by Quintanilla et al. ([@B49]) showed that the anticatalase lentiviral vector reduced VTA catalase activity by 70--80%.](fnbeh-07-00080-g0003){#F3}

![**Dopamine levels in the nucleus accumbens following acute ethanol administration.** Effect of anticatalase vector administration into the ventral tegmental area on dopamine release monitored in the ipsilateral nucleus accumbens. **(A)** Inhibition by anticatalase-lentiviral vector of dopamine efflux into the microdialysis fluid of nucleus accumbens (shell) induced by the systemic administration of ethanol (1 g/kg i.p.). **(B)** Anticatalase-lentiviral vector does not affect dopamine efflux into the microdialysis fluid of nucleus accumbens (shell) induced by d-amphetamine (0.1 mM) or **(C)** Anticatalase-lentiviral vector does not affect dopamine efflux into the microdialysis fluid of nucleus accumbens (shell) induced by KCl (100 mM) added to the microdialysis fluid. (From Karahanian et al., [@B29]).](fnbeh-07-00080-g0004){#F4}

![**Administration of the alcohol dehydrogenase coding gene (rat liver *adh*) into the VTA increases voluntary alcohol intake in rats (UChB) bred as alcohol drinkers. (A)** Four days after the injection of the lentiviral vectors, animals were allowed free availability of 5% (v/v) ethanol and water. Rats significantly (*p* \< 0.001) increased their alcohol intake when injected with a lentiviral vector encoding alcohol dehydrogenase (rADH) (Lenti-ADH) into the ventral tegmental area compared to that observed after treatment with an empty lentiviral vector (control-Lenti) **(A)**. **(B)** No differences in body weight were observed along the experiment in Lenti-ADH-treated rats vs. control-Lenti virus-treated rats. Abscissa: days of ethanol availability. (From Karahanian et al., [@B29]).](fnbeh-07-00080-g0005){#F5}

Brain acetaldehyde as a mediator of the alcohol deprivation effect (ADE)
========================================================================

Sinclair and Senter ([@B65], [@B66]) showed that chronic intake of ethanol by rats, followed by a period of alcohol deprivation and subsequent re-exposure to ethanol leads animals to a marked increase of their ethanol intake above their basal pre-deprivation levels. This effect, termed the "*alcohol deprivation effect*" (ADE), is shown by a marked increase in voluntary intake of ethanol solutions (akin to binge-drinking) over baseline drinking when ethanol is reinstated after the period of alcohol deprivation (Spanagel and Hölter, [@B68]; Rodd-Henricks et al., [@B60]). An ADE can be observed after a short (1--3 days; Sinclair and Li, [@B64]; Agabio et al., [@B1]) or a long (up to 60--75 days) deprivation period (Sinclair et al., [@B67]; Spanagel and Hölter, [@B68]), but is not observed in non-deprived continuously alcohol-treated animals, suggesting that chronic exposure to ethanol alone is not sufficient to produce such a marked increase in ethanol intake (Spanagel and Hölter, [@B68]). Examination of the ADE phenomenon has revealed that at least 3--4 weeks of a continuous alcohol-drinking experience are required before deprivation to elicit an ADE (Spanagel and Hölter, [@B68]).

A number of studies showed that repeated alcohol intake--deprivation--re-administration episodes increase the expression of ADE (see Rodd et al., [@B58]) and Vengeliene and colleagues ([@B78]) have shown that the motivational and reinforcing effects of ethanol are increased in the ADE condition, as animals experiencing the ADE will increase their work to procure ethanol.

Tampier et al. ([@B73]) asked whether in the ADE condition a greater reinforcing effect of ethanol, leading to binge drinking, is also mediated by acetaldehyde (thus, also by products generated from acetaldehyde). It was postulated that if increases in ethanol intake induced by ADE were mediated by acetaldehyde, inhibition of VTA catalase synthesis by microinjection of an anticatalase lentiviral vector should inhibit ADE binge-drinking. To test this question rats were allowed for 60 days 24-h access to 10 and 20% ethanol solutions and water. On day 61, rats were divided into 2 groups matched for similar 24-h alcohol consumption and preference. One group received an intracerebral administration of the control lentiviral vector and was immediately deprived for 15 consecutive days of both the 10 and 20% ethanol solution, while water was the sole fluid available. The second group was injected into the VTA the anticatalase-Lenti-shRNA. As for the viral control group, these rats were returned to their home cage and deprived for 15 days of both 10 and 20% ethanol solutions. Following the 15 days of ethanol deprivation, re-exposure to free-choice intake of 10 and 20% ethanol and water started at 1 PM (on a normal daily cycle) and lasted for 7 days. Alcohol intake was recorded in all groups on the *first hour* of re-exposure (also for 24 h after alcohol re-exposure each day for 7 days; data not shown see Tampier et al., [@B73]). Thereafter, rats received a second period of 15 days of ethanol deprivation and further 7 days of ethanol drinking; again ethanol intake on the first hour of re-intake was recorded. Figure [6](#F6){ref-type="fig"} indicates that (1) UChB rats reproduced the ADE binge drinking condition showing large amounts of ethanol consumed on the first hour post ethanol deprivation (achieving an intoxicating 2 g/kg/60 min) (2) subsequent deprivation ADE cycles increased ethanol intake with a greater consumption of the more concentrated ethanol solution (in line with a more reinforcing effect of ethanol after ADE), and (3) the increased in ethanol intake in the ADE condition was strongly inhibited by the anticatalase vector. After the second deprivation cycle ethanol intake was inhibited by 80%. The above study strongly suggests possible therapeutic avenues in the treatment of alcoholism. It should be noted that administration of viral vectors is used in human therapies (Kaplitt et al., [@B28]) and are approved by agencies such as the U.S. Food and Drug Administration (FDA). Additional studies are being conducted (Karahanian et al. under review) to determine if an overexpression of rat ALDH2 in the VTA also inhibits the ADE-induced increases in ethanol intake.

![**Increased ethanol intake by UChB rats chronically exposed to ethanol, subsequently deprived and ethanol re-exposed.** Marked inhibition of intake following the administration of an anticatalase lentiviral vector. Animals with *ad-libitum* access to 10 and 20% ethanol and water for 60 days. Baseline data correspond to the average of ethanol intake restricted to only 1 h a day, for 7 days immediately prior to alcohol deprivation. A single intra-ventral tegmental area injection of an anticatalase-lentiviral vector inhibited the first 1-h ethanol intake after the first and second ethanol deprivation (ADE) periods of 15 days. The total height of each bar represents the sum of ethanol intake (g ethanol/kg/60 min) of the 10% solution (empty bars) plus that of the 20% solution (gray bars). The -/ /- symbol in the *x*-axis represents the 15-day deprivation period. **(A)** Control viral vector. **(B)** Anticatalase viral vector. Arrows indicate the administration of either control lentiviral vector or anticatalase-lentiviral vector prior to the 15 days of deprivation. The first and second re-exposure consumptions were significantly different from baseline. The inhibition induced by anticatalase vector administration was 67% (*p* \< 0.001) after the first deprivation period, and 80% (*p* \< 0.001) after the second deprivation period. Note also the marked increases in ethanol binge-drinking induced in control vector treated animals after the first and second ethanol intake and deprivation cycles (From Tampier et al., [@B73]).](fnbeh-07-00080-g0006){#F6}

Conclusions {#s1}
===========

Gene-based specific modifications show that an increased liver generation of acetaldehyde, leading to increased blood acetaldehyde levels, results in aversion to ethanol in animals. Similarly, aversion to ethanol results from an increased acetaldehyde level resulting from the inhibition of liver aldehyde dehydrogenase-2 synthesis. The situation is radically different when acetaldehyde is generated in the brain. When the brain ventral tegmental area is endowed with an increased ability to generate acetaldehyde the reinforcing effects of ethanol are increased, while a highly specific inhibition of catalase synthesis virtually abolishes the reinforcing effects of ethanol as seen by a complete abolition of ethanol intake. Data show two divergent effects of increases in acetaldehyde generation: aversive in the periphery but reinforcing in the brain.
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